NCT03551171 - The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

May 3, 2018

Study Completion Date

July 10, 2018

Conditions

Ovarian Cancer

Interventions

DRUG

ZL-2306 (niraparib)

"About 30 subjects will be enrolled to the study, and randomised into 300mg, 200mg and 100mg dose groups (about 10 subjects per group).~All subjects will be randomised into indicated dose group (300mg, 200mg or 100mg) at the first day of the first cycle. A single administration of ZL-2306 (niraparib) will be given to the subjects at indicated dose."

Trial Locations (6)

100000

Beijing Cancer Hospital, Beijing

150000

Haerbin Medical University Cancer Hospital, Harbin

200000

Fudan University Shanghai Cnacer Center, Shanghai

410013

Hunan Cancer Hospital, Changsha

510000

Sun Yat-sen University Cancer Center, Guangzhou

610000

The West China Second UniversityHospital of Sichuan University, Chengdu

All Listed Sponsors

lead

Zai Lab (Shanghai) Co., Ltd.

INDUSTRY